In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Aventis, Millennium sign $450mm anti-inflammatory drug deal

Executive Summary

Millennium Pharmaceuticals and Aventis will jointly discover, develop, and co-promote anti-inflammatory drugs in North America under terms of a deal worth about $450mm to Millennium. The partners will also develop new drug discovery technologies.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register